Schrodinger Inc: Unternehmensprofil, Finanzberichte & Marktperformance

mehr Informationen über Schrodinger Inc Unternehmen

Schrodinger, Inc. operates a physics-based computational platform that enables the discovery of molecules for drug development and materials applications. The software platform is used by biopharmaceutical and industrial companies, academic institutions, and government laboratories around the world. The Company operates through two segments: Software and Drug Discovery. The Software segment is focused on selling its software to transform drug discovery across the life sciences industry, as well as to customers in materials science industries. The Drug Discovery segment is focused on building a diverse portfolio of preclinical and clinical programs, internally and through collaborations, that have advanced to various stages of discovery and development. The Company's pipeline of drug discovery programs includes SGR-1505 (MALT1 Inhibitor), SGR-2921 (CDC7 Inhibitor), SGR-3515 (WEE1 Inhibitor). Its software was used by researchers around the world at more than 1,760 academic institutions.

Schrodinger Inc Informationen



BörsenkürzelSDGR

Name des UnternehmensSchrodinger Inc

IPO-datumFeb 06, 2020

CEODr. Ramy Farid, Ph.D.

Anzahl der mitarbeiter891

WertpapierartOrdinary Share

GeschäftsjahresendeFeb 06

Addresse1540 Broadway

StadtNEW YORK

BörseNASDAQ Global Select Consolidated

LandUnited States of America

Postleitzahl10036

Telefon15032991150

Websitehttps://www.schrodinger.com

BörsenkürzelSDGR

IPO-datumFeb 06, 2020

CEODr. Ramy Farid, Ph.D.

Führungskräfte von Schrodinger Inc



Name

Name/Position

Position

Aktienbesitz

Veränderung

Dr. Richard A. Friesner, Ph.D.

Director

1.24M

+0.49%

Mr. Kenneth Patrick (Patrick) Lorton

Executive Vice President, Chief Operating Officer - Software

36.99K

-30.96%

Ms. Margaret Dugan, M.D.

Chief Medical Officer

24.57K

-5.37%

Ms. Yvonne Tran, J.D.

Chief People Officer, Executive Vice President, Chief Legal Officer

23.64K

+112.26%

Mr. Arun Oberoi

Independent Director

12.25K

+95.95%

Dr. Rosana Kapeller-Libermann, M.D., Ph.D.

Independent Director

12.25K

+95.95%

Michael M. Lynton ,

Independent Chairman of the Board

12.25K

+95.95%

Ms. Bridget Anne Van Kralingen

Independent Director

11.50K

+14.99%

Mr. Mannix Aklian

Executive Vice President, Chief Commercial Officer, Global Head of Software Sales & Marketing

--

Mr. Gary Ginsberg, J.D.

Independent Director

--

Name

Name/Position

Position

Aktienbesitz

Veränderung

Dr. Richard A. Friesner, Ph.D.

Director

1.24M

+0.49%

Mr. Kenneth Patrick (Patrick) Lorton

Executive Vice President, Chief Operating Officer - Software

36.99K

-30.96%

Ms. Margaret Dugan, M.D.

Chief Medical Officer

24.57K

-5.37%

Ms. Yvonne Tran, J.D.

Chief People Officer, Executive Vice President, Chief Legal Officer

23.64K

+112.26%

Mr. Arun Oberoi

Independent Director

12.25K

+95.95%

Dr. Rosana Kapeller-Libermann, M.D., Ph.D.

Independent Director

12.25K

+95.95%

Umsatzaufteilung

Währung: USDAktualisiert: Mon, Oct 6

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2021

FY2020

FY2019

Nach GeschäftsbereichUSD

Name

Umsatz

Anteil

On-premise software

15.74M

28.75%

Drug discovery services

13.94M

25.46%

Hosted software

11.13M

20.32%

Software maintenance

6.78M

12.38%

Contribution

4.51M

8.24%

Andere

2.66M

4.85%

Nach RegionUSD

Name

Umsatz

Anteil

United States

34.05M

62.18%

EMEA

13.56M

24.77%

APAC

6.97M

12.73%

Rest of World

175.00K

0.32%

Nach Geschäftsbereich

Nach Region

Nach GeschäftsbereichUSD

Name

Umsatz

Anteil

On-premise software

15.74M

28.75%

Drug discovery services

13.94M

25.46%

Hosted software

11.13M

20.32%

Software maintenance

6.78M

12.38%

Contribution

4.51M

8.24%

Andere

2.66M

4.85%

Aktionärsstatistik

Aktualisiert: Sat, Nov 1

Aktionäre

Aktionärstypen

Aktionäre

Anteil

BlackRock Institutional Trust Company, N.A.

12.66%

Bill & Melinda Gates Foundation Trust

10.82%

The Vanguard Group, Inc.

9.81%

Rubric Capital Management LP

7.75%

Amova Asset Management Co., Ltd.

7.06%

Andere

51.89%

Aktionäre

Anteil

BlackRock Institutional Trust Company, N.A.

12.66%

Bill & Melinda Gates Foundation Trust

10.82%

The Vanguard Group, Inc.

9.81%

Rubric Capital Management LP

7.75%

Amova Asset Management Co., Ltd.

7.06%

Andere

51.89%

Aktionärstypen

Aktionäre

Anteil

Investment Advisor

46.69%

Investment Advisor/Hedge Fund

29.18%

Hedge Fund

19.49%

Endowment Fund

10.82%

Individual Investor

2.64%

Research Firm

2.60%

Bank and Trust

1.72%

Pension Fund

0.91%

Venture Capital

0.13%

Institutionelle Beteiligung



Aktualisiert: Wed, Oct 1

Berichtszeitraum

Anzahl der Institutionen

Gehaltenen Aktien

Anteil

Veränderung

2025Q3

545

71.77M

111.28%

-2.08M

2025Q2

572

66.46M

103.14%

-5.60M

2025Q1

593

67.21M

104.69%

-5.43M

2024Q4

576

64.44M

100.89%

-9.04M

2024Q3

581

67.44M

105.91%

-6.15M

2024Q2

573

64.76M

101.80%

-8.12M

2024Q1

574

63.48M

100.05%

-5.40M

2023Q4

584

62.06M

98.56%

-7.64M

2023Q3

586

63.62M

101.35%

-15.42M

2023Q2

584

64.04M

102.20%

-7.30M

Aktionärsaktivitäten



Name

Gehaltenen Aktien

Anteil

Veränderung

Änderung%

Datum

BlackRock Institutional Trust Company, N.A.

8.17M

12.68%

+419.13K

+5.41%

Jun 30, 2025

Bill & Melinda Gates Foundation Trust

6.98M

10.83%

--

Jun 30, 2025

The Vanguard Group, Inc.

6.60M

10.25%

+74.93K

+1.15%

Jun 30, 2025

Rubric Capital Management LP

5.00M

7.76%

+200.00K

+4.17%

Jun 30, 2025

Amova Asset Management Co., Ltd.

3.65M

5.66%

+187.53K

+5.42%

Jun 30, 2025

Cadian Capital Management LP

3.05M

4.73%

+1.94M

+175.65%

Jun 30, 2025

Stephens Investment Management Group, LLC

2.26M

3.51%

+291.39K

+14.79%

Jun 30, 2025

State Street Investment Management (US)

2.19M

3.39%

-26.19K

-1.18%

Jun 30, 2025

MFS Investment Management

1.49M

2.32%

-598.55K

-28.60%

Jun 30, 2025

ARK Investment Management LLC

1.96M

3.04%

-335.26K

-14.61%

Jun 30, 2025

Verbundene ETFs



Aktualisiert: Thu, Nov 6

Name

Anteil

ARK Genomic Revolution ETF

3.29%

TrueShares Technology, AI & Deep Learning ETF

1.87%

Global X HealthTech ETF

1.47%

SPDR FactSet Innovative Technology ETF

0.99%

Franklin Exponential Data ETF

0.82%

WisdomTree BioRevolution Fund

0.75%

Invesco S&P SmallCap Health Care ETF

0.71%

Franklin Genomic Advancements ETF

0.47%

First Trust Nasdaq Lux Digi Health Solutions ETF

0.45%

First Trust Multi-Manager Small Cap Opportunities ETF

0.43%

ARK Genomic Revolution ETF

Anteil3.29%

TrueShares Technology, AI & Deep Learning ETF

Anteil1.87%

Global X HealthTech ETF

Anteil1.47%

SPDR FactSet Innovative Technology ETF

Anteil0.99%

Franklin Exponential Data ETF

Anteil0.82%

WisdomTree BioRevolution Fund

Anteil0.75%

Invesco S&P SmallCap Health Care ETF

Anteil0.71%

Franklin Genomic Advancements ETF

Anteil0.47%

First Trust Nasdaq Lux Digi Health Solutions ETF

Anteil0.45%

First Trust Multi-Manager Small Cap Opportunities ETF

Anteil0.43%

Dividende



In den vergangenen 5 Jahren wurden insgesamt 0.00 USD an Dividenden ausgeschüttet.

Datum

Dividende

Stichtag für die Aktienregistrierung

Zahltag

Ex-Dividendentag

Keine Daten

Aktien-Split



Datum

Art

Verhältnis

Keine Daten

Datum

Art

Verhältnis

Keine Daten